Oculis (NASDAQ:OCS – Get Free Report) had its target price decreased by analysts at Guggenheim to $40.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim‘s price target points to a potential upside of 442.37% from the stock’s previous close.
Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research note on Thursday, October 15th. JPMorgan Chase & Co. reduced their price target on shares of Oculis from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Friday, August 14th. HC Wainwright reiterated a “buy” rating and set a $39.00 price objective on shares of Oculis in a research report on Wednesday, October 21st. Finally, Wall Street Zen upgraded shares of Oculis from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.89.
Get Our Latest Stock Analysis on Oculis
Oculis Stock Performance
NASDAQ:OCS traded down $0.26 during mid-day trading on Wednesday, reaching $7.38. 69,927 shares of the stock were exchanged, compared to its average volume of 418,116. The stock has a market capitalization of $427.60 million, a P/E ratio of -4.26 and a beta of 0.67. The company has a 50 day simple moving average of $9.53 and a 200-day simple moving average of $18.62. The company has a quick ratio of 8.35, a current ratio of 8.35 and a debt-to-equity ratio of 0.01. Oculis has a 1 year low of $7.11 and a 1 year high of $34.47.
Oculis (NASDAQ:OCS – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.10. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.26 million. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%. Analysts anticipate that Oculis will post -2.01 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Oculis
Several institutional investors have recently bought and sold shares of OCS. Alps Advisors Inc. increased its holdings in shares of Oculis by 40.7% in the third quarter. Alps Advisors Inc. now owns 81,619 shares of the company’s stock valued at $762,000 after purchasing an additional 23,600 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Oculis during the third quarter worth about $74,000. Squarepoint Ops LLC increased its holdings in Oculis by 326.4% in the 2nd quarter. Squarepoint Ops LLC now owns 61,605 shares of the company’s stock valued at $854,000 after buying an additional 47,158 shares during the period. Braidwell LP bought a new position in Oculis in the 2nd quarter valued at about $11,570,000. Finally, Bank of America Corp DE raised its position in shares of Oculis by 9.1% in the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock valued at $1,855,000 after buying an additional 5,813 shares in the last quarter. Institutional investors own 22.30% of the company’s stock.
Oculis Company Profile
Oculis is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company’s research is centered on therapies that can be administered directly to the eye, including topical ophthalmic formulations and other approaches designed to improve drug delivery, efficacy, and patient convenience.
Oculis has developed a pipeline addressing ophthalmic conditions such as retinal diseases, diabetic macular edema, dry eye disease, and other disorders that can impair vision.
Recommended Stories
- Five stocks we like better than Oculis
- High Voltage Returns: Talen Energy Powers the Data Center Rush
- 3 Dividend Increases Above 10%, But Which Offers the Most Income?
- Meta’s $100 Billion AI Financing Plan Has a Catch for Existing Shareholders
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
